Guidelines
Copyright ©The Author(s) 2021.
World J Clin Oncol. Mar 24, 2021; 12(3): 115-143
Published online Mar 24, 2021. doi: 10.5306/wjco.v12.i3.115
Table 6 Summary of the main studies of prophylactic cranial irradiation in small cell lung cancer
PCI in SCLC

Ref.
Stage (LS or ES)
Phase
Treatment
Survival
P value
Incidence of BM
P value
Level of evidence
Arriagada et al[144] 2002LSIIIPCI; no PCI18% at 5 yr; 15% at 5 yr0.0620% at 5 yr; 37% at 5 yr< 0.001A I
Aupérin et al[33] 1999LSMeta-analysisPCI; no PCI20.7%; 15.3%0.010.38; 0.570.001A I
Warde et al[20] 1992LSMeta-analysisPCI; no PCIHR 0.82HR 0.48A I
Takahashi et al[122] 2017ESIIIPCI; MRI + no PCI13.6 mo; 11.6 mo48%; 69%A I
Rusthoven et al[81] 2020IIIWBRT; SRS5.2 mo; 6.5 mo0.003A I
Yin et al[145] 2019Meta-analysisPCI; observationHR 0.81< 0.001HR 0.45< 0.001A II
De Ruysscher et al[146] 2018IIIPCI; observation24.2 mo; 21.9 mo0.567%; 27.2%0.001A I
Slotman et al[38] 2007ESIIIPCI; no PCI6.7 mo; 5.4 mo15% at 1 yr; 40% at 1 yr< 0.001A I
Le Péchoux et al[154] 2009LSIIIStandard dose PCI; high dose PCI42%; 37%0.0529% at 2 yr; 23% at 2 yr0.18A I
Ref.Stage (LS or ES)PhaseTreatmentMedian SurvivalP valueIncidence of neurological deficitP valueLevel of evidence
Yang et al[157] 2018LSMeta-analysisPCI; no PCIHR 0.52RR 0.5A I
Viani et al[148] 2012LS-ESMeta-analysisPCI; no PCIOR 0.730.01
Ge et al[149] 2018ESMeta-analysisPCI; no PCIHR 0.57< 0.001RR 0.47< 0.01A I
Brown et al[164] 2020IIIHA + WBRT + Memantine; WBRT + MemantineLearning 11.5%, memory 16.4%; learning 24.7%, memory 33.3%0.049; 0.02AI
van Meerbeeck et al[165] 2019IIIPCI; PCI + HAHVLT-R 28%; 29%> 0.05A I
De Dios et al[167] 2019LS-ESIIIPCI; PCI + HAFCSRT 21.7%, 32.6%, and 18.5% at 3, 6 and 12 mo; FCSRT 5.1%, 7.3% and 3.8% at 3, 6 and 12 mo< 0.05AI